Monopar Therapeutics Inc
MNPR
查看详细走势图
57.750USD
+0.870+1.53%
收盘 02/06, 16:00（美东）报价延迟15分钟
384.78M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.53%
5天
-4.36%
1月
-11.17%
6月
+44.01%
今年开始到现在
-11.56%
1年
+19.17%
查看详细走势图
TradingKey Monopar Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Monopar Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名114/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价112.00。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Monopar Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Monopar Therapeutics Inc亮点
亮点风险
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-14.59，处于3年历史低位
机构加仓
最新机构持股4.56M股，环比增加16.89%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值293.82K
分析师目标
根据
14
位分析师
买入
评级
112.000
目标均价
+88.46%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Monopar Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Monopar Therapeutics Inc简介
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
公司代码MNPR
公司Monopar Therapeutics Inc
CEORobinson (Chandler D)
网址https://www.monopartx.com/
相关品种
